Education
About Us
Working with TipRanks
Follow Us
Bausch + Lomb Corporation (BLCO)
NYSE:BLCO
BLCO Stock Chart & Stats
$17.00
$0.21(1.15%)
At close: 4:00 PM EST
$17.00
$0.21(1.15%)
Day’s Range― - ―
52-Week Range$10.45 - $17.86
Previous CloseN/A
Volume107.99K
Average Volume (3M)405.48K
Market Cap
$6.02B
Enterprise Value$10.67B
Total Cash (Recent Filing)$310.00M
Total Debt (Recent Filing)$4.95B
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Feb 18, 2026EPS Estimate
0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.18
Shares Outstanding354,189,800
10 Day Avg. Volume391,487
30 Day Avg. Volume405,477
Financial Highlights & Ratios
PEG Ratio-0.93
Price to Book (P/B)0.98
Price to Sales (P/S)1.33
P/FCF Ratio-107.69
Enterprise Value/Market Cap1.77
Enterprise Value/Revenue2.14
Enterprise Value/Gross Profit3.61
Enterprise Value/Ebitda20.96
Forecast
1Y Price Target
$18.11Price Target Upside6.53% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Contact Lens Market Share GrowthManagement projects contact lens growth that outpaces the broader market, implying share gains that could strengthen the consumer business and organic growth profile.
Contract Termination And Pricing DisciplineTermination of the low-margin CVS distribution agreement should allow higher pricing and improved Xiidra margins, supporting overall profitability for the product franchise.
Pipeline Commercial UpsidePipeline assets collectively have multi-billion-dollar peak sales potential, offering a clear route to meaningful revenue and earnings upside if clinical and regulatory milestones are achieved.
Bears Say
Lack Of Near-term Valuation CatalystsAnalysts note the absence of identifiable catalysts to drive near-term multiple expansion, which could keep the stock range-bound unless new growth drivers emerge.
Leverage And Parent Separation UncertaintyHigh leverage together with limited visibility on a full separation from the parent company could constrain strategic flexibility and weigh on valuation until deleveraging is demonstrably achieved.
Optimistic Long-range Plan AssumptionsLong-range revenue and margin targets appear optimistic and may reflect best-case scenarios, creating execution risk if underlying assumptions prove ambitious.
Bausch + Lomb Corporation News
BLCO FAQ
What was Bausch + Lomb Corporation’s price range in the past 12 months?
Bausch + Lomb Corporation lowest stock price was $10.45 and its highest was $17.86 in the past 12 months.
What is Bausch + Lomb Corporation’s market cap?
Bausch + Lomb Corporation’s market cap is $6.02B.
When is Bausch + Lomb Corporation’s upcoming earnings report date?
Bausch + Lomb Corporation’s upcoming earnings report date is Feb 18, 2026 which is in 8 days.
How were Bausch + Lomb Corporation’s earnings last quarter?
Bausch + Lomb Corporation released its earnings results on Oct 29, 2025. The company reported $0.18 earnings per share for the quarter, beating the consensus estimate of $0.16 by $0.02.
Is Bausch + Lomb Corporation overvalued?
According to Wall Street analysts Bausch + Lomb Corporation’s price is currently Undervalued.
Does Bausch + Lomb Corporation pay dividends?
Bausch + Lomb Corporation does not currently pay dividends.
What is Bausch + Lomb Corporation’s EPS estimate?
Bausch + Lomb Corporation’s EPS estimate is 0.36.
How many shares outstanding does Bausch + Lomb Corporation have?
Bausch + Lomb Corporation has 354,189,800 shares outstanding.
What happened to Bausch + Lomb Corporation’s price movement after its last earnings report?
Bausch + Lomb Corporation reported an EPS of $0.18 in its last earnings report, beating expectations of $0.16. Following the earnings report the stock price went up 1.776%.
Which hedge fund is a major shareholder of Bausch + Lomb Corporation?
Currently, no hedge funds are holding shares in BLCO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bausch + Lomb Corporation Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$18.11 (6.53% Upside)
$18.11 (6.53% Upside)
Blogger Sentiment
Neutral
BLCO Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 3.4M Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-6.00%
12-Months-Change
Fundamentals
Return on Equity
-4.69%
Trailing 12-Months
Asset Growth
2.35%
Trailing 12-Months
Company Description
Bausch + Lomb Corporation
Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.
BLCO Company Deck
BLCO Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook with strong revenue growth across multiple segments, particularly in Pharmaceuticals and Vision Care. While there are concerns about gross margin and tariff impacts, the company's recovery from the enVista recall and successful cash flow optimization demonstrate resilience and strategic management.View all BLCO earnings summariesBLCO Stock 12 Month Forecast
Average Price Target
$18.11
▲(6.53% Upside)
Technical Analysis
Ownership Overview
0.60% Insiders
0.54% Mutual Funds
<0.01% Other Institutional Investors
98.47% Public Companies and
Individual Investors